“Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study”, J of Skin, vol. 8, no. 6, p. s451, Nov. 2024, doi: 10.25251/skin.8.supp.451.